Spots Global Cancer Trial Database for lurbinectedin
Every month we try and update this database with for lurbinectedin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA | NCT04291937 | Small Cell Lung... | Lurbinectedin | 18 Years - | Jazz Pharmaceuticals | |
| Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer. | NCT04358237 | Small Cell Lung... | Lurbinectedin Pembrolizumab | 18 Years - | Blanco, Dr Antonio Calles MD | |
| Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment | NCT05101265 | Advanced Solid ... Hepatic Impairm... | Lurbinectedin Lurbinectedin | 18 Years - | PharmaMar | |
| Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors | NCT01980667 | Advanced Solid ... | lurbinectedin (... Cisplatin | 18 Years - | PharmaMar | |
| Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome | NCT01314599 | Acute Leukemia | PM01183 1 mg Po... | 18 Years - | PharmaMar | |
| A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer | NCT05091567 | Small-Cell Lung... | Atezolizumab Lurbinectedin Carboplatin Etoposide | 18 Years - | Hoffmann-La Roche | |
| Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors | NCT01970540 | Endometrial Ade... Neuroendocrine ... Small-cell Lung... | lurbinectedin (... Doxorubicin | 18 Years - 75 Years | PharmaMar | |
| A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer | NCT01525589 | Breast Cancer | PM01183 | 18 Years - 75 Years | PharmaMar | |
| Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors | NCT05072106 | Advanced Solid ... | Lurbinectedin Bosentan | 18 Years - | PharmaMar | |
| Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | NCT02611024 | Advanced Solid ... Glioblastoma Soft Tissue Sar... Endometrial Car... Epithelial Ovar... Mesothelioma Gastroenteropan... SCLC Gastric Carcino... Pancreatic Aden... Colorectal Carc... Neuroendocrine ... | Lurbinectedin Irinotecan | 18 Years - | PharmaMar | |
| Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer | NCT05740566 | Small Cell Lung... | Tarlatamab Lurbinectedin Topotecan Amrubicin | 18 Years - | Amgen | |
| Lurbinectedin + Doxorubicin In Leiomyosarcoma | NCT05099666 | Advanced Soft-t... Metastatic Soft... Advanced Leiomy... Leiomyosarcoma ... | Lurbinectedin Doxorubicin | 18 Years - | Massachusetts General Hospital | |
| Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) | NCT05153239 | Relapsed Small ... | Irinotecan Lurbinectedin Irinotecan Topotecan Lurbinectedin | 18 Years - | PharmaMar | |
| Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) | NCT05153239 | Relapsed Small ... | Irinotecan Lurbinectedin Irinotecan Topotecan Lurbinectedin | 18 Years - | PharmaMar | |
| Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer | NCT05800587 | Lung Cancer Small-cell Lung... Non Small Cell ... | Carboplatin Pemetrexed Paclitaxel Nab paclitaxel Docetaxel Gemcitabine Etoposide Irinotecan Topotecan Lurbinectedin | 18 Years - | Fox Chase Cancer Center | |
| Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas | NCT06217536 | Locally Advance... | Lurbinectedin Radiotherapy Non-investigati... | 18 Years - | University of California, San Francisco | |
| Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma | NCT06088290 | Leiomyosarcoma | Lurbinectedin Doxorubicin | 18 Years - | PharmaMar | |
| Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors | NCT01980667 | Advanced Solid ... | lurbinectedin (... Cisplatin | 18 Years - | PharmaMar | |
| A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer | NCT01525589 | Breast Cancer | PM01183 | 18 Years - 75 Years | PharmaMar | |
| LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma | NCT05876715 | Advanced Soft-t... | Lurbinectedin | 18 Years - 90 Years | Sarcoma Oncology Research Center, LLC | |
| Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome | NCT01314599 | Acute Leukemia | PM01183 1 mg Po... | 18 Years - | PharmaMar | |
| LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma | NCT05876715 | Advanced Soft-t... | Lurbinectedin | 18 Years - 90 Years | Sarcoma Oncology Research Center, LLC | |
| Lurbinectedin in FET-Fused Tumors | NCT05918640 | Ewing Sarcoma Desmoplastic Sm... Pediatric Cance... Undifferentiate... | Lurbinectedin | 10 Years - | Children's Hospital of Philadelphia | |
| A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | NCT06203210 | Small Cell Lung... | Ifinatamab deru... Topotecan Amrubicin Lurbinectedin | 18 Years - | Daiichi Sankyo | |
| Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma. | NCT03213301 | Malignant Pleur... | Lurbinectedin | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors | NCT01970540 | Endometrial Ade... Neuroendocrine ... Small-cell Lung... | lurbinectedin (... Doxorubicin | 18 Years - 75 Years | PharmaMar | |
| Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors | NCT01980667 | Advanced Solid ... | lurbinectedin (... Cisplatin | 18 Years - | PharmaMar | |
| Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma | NCT05734066 | Refractory Ewin... Relapsed Ewing ... Ewing Sarcoma | Lurbinectedin | 2 Years - 30 Years | Jazz Pharmaceuticals | |
| Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer | NCT05636111 | Ovarian Cancer | Paclitaxel Bevacizumab Lurbinectedin | 18 Years - | M.D. Anderson Cancer Center | |
| Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma. | NCT03213301 | Malignant Pleur... | Lurbinectedin | 18 Years - | Swiss Group for Clinical Cancer Research | |
| A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer | NCT05091567 | Small-Cell Lung... | Atezolizumab Lurbinectedin Carboplatin Etoposide | 18 Years - | Hoffmann-La Roche | |
| Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC | NCT04610658 | Small-cell Lung... Relapsed Small ... Recurrent Small... | Nivolumab Ipilimumab Lurbinectedin | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma | NCT06088290 | Leiomyosarcoma | Lurbinectedin Doxorubicin | 18 Years - | PharmaMar | |
| Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors | NCT01970553 | Specific Advanc... | lurbinectedin (... Gemcitabine | 18 Years - 75 Years | PharmaMar | |
| Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer | NCT05636111 | Ovarian Cancer | Paclitaxel Bevacizumab Lurbinectedin | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Trilaciclib and Lurbinectidin | NCT05578326 | Lung Cancer Small-cell Lung... | Trilaciclib Lurbinectedin | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma. | NCT03213301 | Malignant Pleur... | Lurbinectedin | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas | NCT06217536 | Locally Advance... | Lurbinectedin Radiotherapy Non-investigati... | 18 Years - | University of California, San Francisco | |
| Lurbinectedin in FET-Fused Tumors | NCT05918640 | Ewing Sarcoma Desmoplastic Sm... Pediatric Cance... Undifferentiate... | Lurbinectedin | 10 Years - | Children's Hospital of Philadelphia | |
| Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER) | NCT06228066 | Small Cell Carc... High Grade Neur... | Lurbinectedin Avelumab | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) | NCT05153239 | Relapsed Small ... | Irinotecan Lurbinectedin Irinotecan Topotecan Lurbinectedin | 18 Years - | PharmaMar | |
| Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC | NCT04610658 | Small-cell Lung... Relapsed Small ... Recurrent Small... | Nivolumab Ipilimumab Lurbinectedin | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors | NCT05072106 | Advanced Solid ... | Lurbinectedin Bosentan | 18 Years - | PharmaMar | |
| Lurbinectedin in FET-Fused Tumors | NCT05918640 | Ewing Sarcoma Desmoplastic Sm... Pediatric Cance... Undifferentiate... | Lurbinectedin | 10 Years - | Children's Hospital of Philadelphia |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
